Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: Do children of all ages respond equally?

Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Vaccine (Impact Factor: 3.62). 06/2010; 28(27):4376-83. DOI: 10.1016/j.vaccine.2010.04.058
Source: PubMed


We assessed the effect of age on immunogenicity to trivalent inactivated influenza vaccine (TIV) by comparing the immune responses to influenza vaccine antigens among three age cohorts of vaccine-naïve children aged 6-11 months, 12-17 months, and 18-23 months. In children 6-23 months of age, antibody responses to TIV appear to increase with increasing age. Despite this finding, TIV was immunogenic even in the youngest age group evaluated, further establishing its value as a tool to protect young children from influenza. The role of age should be considered when assessing improved vaccines to enhance TIV immunogenicity and effectiveness in younger children.

6 Reads
  • Source
    • "The immune response in infants and young children by vaccination is lower than that in older children and adults (8, 13-15). Even at an age of < 2 yr, the antibody responses increase with age (16). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to compare the immune response induced by natural infection with 2009 pandemic influenza A/H1N1 (pH1N1) virus and by monovalent pH1N1 vaccination in children and adolescents. This cross-sectional clinical study was conducted at 3 hospitals in Korea from February to May 2010. A total of 266 healthy subjects aged from 6 months to 18 yr were tested for the presence of the antibody against pH1N1 using hemagglutination inhibition (HI) test. Information about pH1N1 vaccination and laboratory-confirmed pH1N1 infection history was obtained. The overall rate of HI titers of ≥ 1:40 against pH1N1 was 38.7%, and the geometric mean titer (GMT) was 20.5. Immunogenicity of pH1N1 vaccination only was reflected by a 41.1% of seroprotection rate and a GMT of 22.5. Immunogenicity of natural infection only was reflected by a 61.0% of seroprotection rate and a GMT of 40.0. GMT was significantly higher in the subjects of natural infection group than in the subjects of pH1N1 vaccination group (P < 0.001). The immune responses induced by natural pH1N1 infection exceed those induced by pH1N1 vaccinations.
    Journal of Korean medical science 02/2013; 28(2):274-9. DOI:10.3346/jkms.2013.28.2.274 · 1.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rational drug design based on molecular targets is starting to revolutionize cancer care. To maximize its potential for patients, a concomitant leveraging of molecular knowledge for selection of patients to future and current therapeutic options is paramount. The terms "individualized", "personalized", or "precision therapy" are currently used to describe these efforts. Here, we summarize current knowledge for selection of systemic targeted and cytotoxic therapy for patients with non-small-cell lung cancer. Based on this knowledge, we present a potential decision algorithm to best select patients for currently available therapies, which include the treatment options single-agent erlotinib or gefitinib, the ALK inhibitor crizotinib, double agent gemcitabine and platinum, double agent platinum and pemetrexed, and as a default option a taxane combined with a non-platinum drug, for instance a vinca alkaloid. The addition of bevacizumab to double-agent chemotherapy is also discussed. Currently available data on predictive biomarkers are largely based on subgroup or companion biomarker analyses of patient cohorts or clinical trials. Current and emerging markers must be incorporated prospectively into the design of clinical trials that test novel and established agents to better understand their clinical utility and to refine selection parameters and marker interactions. Future development will lead to increasing complexity in clinical decision making with substantial anticipated benefits to patients including increased therapeutic efficacy, reduced toxicity, and better quality of life.
    Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 11/2010; 13(6):196-204. DOI:10.1016/j.drup.2010.10.001 · 9.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza represents a major sanitary and socio-economic burden and vaccination is universally considered the most effective strategy for preventing the disease and its complications. Traditional influenza vaccines have been on the market since the late 1940s, with million of doses administered annually worldwide, and demonstrated a substantial efficacy and safety. The trivalent inactivated subunit vaccine has been available for more than 25 years and has been studied in healthy children, adults and the elderly and in people affected by underlying chronic medical conditions. We describe vaccine technology focusing on subunit vaccine production procedures and mode of action and provide updated information on efficacy and safety available data. A review of efficacy and safety data in healthy subjects and in high risk populations from major sponsor- and investigator-driven studies. The vaccine showed a good immunogenicity and a favorable safety profile in all target groups. In the panorama of actually available influenza vaccines, trivalent inactivated subunit vaccine represents a well-established tool for preventing flu and the associated complications.
    Expert opinion on biological therapy 01/2011; 11(1):89-98. DOI:10.1517/14712598.2011.541436 · 3.74 Impact Factor
Show more